m.Stock by Mirae AssetOpen Demat Account
m.Stock by Mirae Asset
Aspira Pathlab & Diagnostics Ltd logo

Aspira Pathlab & Diagnostics Ltd Share Price

Current price unavailable.
As on - | -
HealthcareSmall Cap

Volume Analysis

SPOT Pivot Levels

TypeClassicFibonacci
R1 --
R2--
R3--
PP- -
S1--
S2--
S3 --

Ratios

ParticularsDec 2025Sep 2025Jun 2025Mar 2025Dec 2024
ROCE-21.56-15.7-
ROE-23.61-16.97-
EPS-1.521.780.460.70.37

Peer Comparison

No data available
Scrip NamePriceDaily changeM CapPE Ratio1 Year Return

Corporate Action

April 15, 2026
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Aspira Pathlab & Diagnostics Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L85100MH1973PLC289209</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>NA</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>NA</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Company is under the process to appoint Company Secretary</td></tr><tr><td>Designation :-</td><td>Company Secretary</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Balkrishna Talawadekar </td></tr> <tr><td>Designation : -</td><td>Chief Financial Officer</td></tr></table><div> <br/> Date: 15/04/2026<br/><br/></div>
April 15, 2026
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Aspira Pathlab & Diagnostics Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L85100MH1973PLC289209</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Company is under the process to appoint Company Secretary <br/> Designation: Company Secretary <br/> EmailId: info@aspiradiagnostics.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Balkrishna Talawadekar <br/> Designation: Chief Financial Officer <br/> EmailId: balkrishna.talawadekar@aspiradiagnostics.com</div> </div> <div> <br/> Date: 15/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

About Aspira Pathlab & Diagnostics Ltd

Equity img
Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973. ASDL is a leading pathology specialist, with Pan-India presence. It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses. The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providin...
ISIN :INE500C01017

Registered Office

Flat No. 2 RD Shah Building,Shraddanand Road Ghatkopar(W)

Contact number

+ 91-22-71975756/5656

Registrars

MUFG Intime India Pvt Ltd
C-101 247 Park L B S Marg Vikhroli West Mumbai-400083

Contact number

+ 91-22-49186000

Management

Haseeb A Drabu (Chairman)

Pankaj Jashwant Shah (Director)

Open IPO’s

View All

FAQs

The share price of Aspira Pathlab & Diagnostics Ltd on the BSE is - as on -